We speak with Cory Milam, director of the Food and Drug Administration's Office of Innovation about using emerging technology in its decision-making. The FDA is excited about emerging technologies and its potential to better connect its scientists and researchers with data-driven decision-making. Some of its centers are exploring the use of blockchain to get evaluations done between external parties and FDA in a secure manner, and the administration as a whole is looking at electronic health record modification and its impact on patient-data access.
